ACM
KYMR icon

Asymmetry Capital Management’s Kymera Therapeutics KYMR Stock Holding History

Asymmetry Capital Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-89,071
Closed -$5.23M – 31
2021
Q3 		$5.23M Sell
89,071
-34,292
-28% -$1.99M 3.15% 16
2021
Q2 		$5.98M Buy
+123,363
New +$5.36M 4.11% 11

Other funds holding KYMR

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Asymmetry Capital Management's KYMR Position: Q4 2021 in Review

Asymmetry Capital Management sold out of Kymera Therapeutics (KYMR) in Q4 2021, closing a stake of 89,071 shares — an estimated $5.23M sold.

Asymmetry Capital Management first reported a position in KYMR in Q2 2021 and held it in 2 quarters. The position peaked at $5.98M in Q2 2021. 128 funds tracked by Wall St. Rank hold KYMR as of Q4 2021.

  • Asymmetry Capital Management reported no remaining Kymera Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Asymmetry Capital Management sold 89,071 Kymera Therapeutics shares in Q4 2021, an estimated $5.23M.
  • Asymmetry Capital Management first reported a position in Kymera Therapeutics in Q2 2021 and held it in 2 quarters.
  • Asymmetry Capital Management's Kymera Therapeutics position peaked at $5.98M in Q2 2021.
  • 128 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q4 2021.

Based on Asymmetry Capital Management's 13F filing for Q4 2021, filed 19 Jan 2022.